Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline.

Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained $0.55 (10%) to $6.05 in its first day of trading on NASDAQ Thursday after selling 8 million ADSs at $5.50 to raise $44.3 million. Each ADS represents one ordinary share...